Physician profile
Gary Michael Ross
NPI 1639130099
$1,256.57
in general payments reported to CMS, 2019-2025
21 companies · $114 in 2025
The $114 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2020: $150 · 2021: $223 · 2022: $211 · 2023: $239 · 2024: $148 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $500.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $190.02 | 2019-2023 | Trelegy Ellipta |
| Pfizer INC. | $165.42 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $135.01 | 2019-2025 | Verquvo, Belsomra, Rotateq |
| Abbott Laboratories | $129.14 | 2022-2023 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $92.59 | 2019 | |
| Janssen Pharmaceuticals, INC | $81.80 | 2020-2021 | |
| Exact Sciences Corporation | $54.44 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $54.27 | 2024-2025 | Veozah |
| Novo Nordisk INC | $45.55 | 2019-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $41.22 | 2020-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $40.70 | 2022 | |
| Lilly USA, LLC | $37.00 | 2022-2024 | Zepbound |
| Abbvie INC. | $27.24 | 2024 | |
| Eisai INC. | $25.08 | 2020-2021 | |
| Amgen INC. | $24.66 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $23.04 | 2025 | Sublocade |
| Sanofi-Aventis U.S. LLC | $21.97 | 2022 | |
| Sanofi Pasteur INC. | $20.00 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.14 | 2022 | |
| Esperion Therapeutics, INC. | $15.68 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.